Numerous assay methods have been developed to identify small-molecule effectors of protein kinases, but no single method can be applied to all isolated kinases. The authors developed a set of 3 high-throughput screening (HTS)-compatible biochemical assays that can measure 3 mechanistically distinct properties of a kinase active site, with the goal that at least 1 of the 3 would be applicable to any kinase selected as a target for drug discovery efforts. Two assays measure catalytically active enzyme: A dissociation-enhanced lanthanide fluoroimmuno assay (DELFIA) uses an antibody to quantitate the generation of phosphorylated substrate; a second assay uses luciferase to measure the consumption of adenosine triphosphate (ATP) during either phosphoryl-transfer to a peptide substrate or to water (intrinsic ATPase activity). A third assay, which is not dependent on a catalytically active enzyme, measures the competition for binding to kinase between an inhibitor and a fluorescent ATP binding site probe. To evaluate the suitability of these assays for drug discovery, the authors compared their ability to identify inhibitors of a nonreceptor protein tyrosine kinase from the Tec family, interleukin-2-inducible T cell kinase (ITK). The 3 assays agreed on 57% of the combined confirmed hit set identified from screening a 10,208-compound library enriched with known kinase inhibitors and molecules that were structurally similar. Among the 3 assays, the one measuring intrinsic ATPase activity produced the largest number of unique hits, the fewest unique misses, and the most comprehensive hit set, missing only 2.7% of the confirmed inhibitors identified by the other 2 assays combined. Based on these data, all 3 assay formats are viable for screening and together provide greater options for assay design depending on the targeted kinase. (Journal of Biomolecular
INTRODUCTION T HE SEARCH FOR SMALL-MOLECULE KINASE INHIBITORS
has resulted in the recent clinical success of imatinib mesylate (Gleevec ® ) for chronic myeloid leukemia and of gefitinib (Iressa ® ) and erlotinib (Tarceva ® ) for non-small-cell lung cancer. The attractiveness of protein kinases as drug targets has fueled the development of assay methods to identify effectors of their activity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Assay design of protein kinases can be complicated by the diverse means by which members of the gene family are activated. Moreover, an appropriate protein or peptide substrate cannot always be identified or produced, especially for kinases of unknown cellular function. Many assay formats also require specific reagents for readout, such as antibodies or labeled peptides. For these reasons, we sought to put in place a small, universal set of screening-compatible assays, at least one of which could be used to find inhibitors for a majority of recombinant kinases, regardless of whether they were catalytically active or the physiological substrate was known or available.
A common method used for measuring kinase activity is to monitor the transfer of the γ-phosphoryl group from adenosine triphosphate (ATP) to the hydroxyl group of serine, threonine, and/or tyrosine residue(s) in a protein or polypeptide substrate in the presence of a divalent metal ion, usually Mg 2+ or Mn 2+ . 12 Two of the 3 assays in our set measure this phosphoryl-transfer reaction, one directly and one indirectly. The first, a dissociationenhanced lanthanide fluoroimmuno assay (DELFIA), 1 is a solid-phase, nonhomogeneous method that directly quantitates immobilized phosphorylated peptide copolymer, poly(Glu 4 , Tyr 1 ), using an europium chelate-labeled antiphosphotyrosine antibody (Fig. 1A) . This assay requires multiple wash steps and requires both polypeptide substrate and an antibody to phosphorylated substrate. Because the test compound is removed before signal generation, the DELFIA is resistant to test compound interference. The second assay measures kinase catalytic activity indirectly using an ATP-dependent enzyme, firefly luciferase, to monitor the consumption of ATP during the phosphoryl-transfer reaction (Fig. 1B) . In addition, some kinases display intrinsic ATPase activity by which ATP is hydrolyzed in the presence of water with the formation of adenosine diphosphate (ADP) and inorganic phosphate (Fig. 1B) . This intrinsic ATPase activity is catalyzed at the enzyme active site [13] [14] [15] [16] and, like phosphoryl-transfer activity, can be measured using the luciferase luminescence assay. An advantage of assay development for kinases that display measurable intrinsic ATPase activity is the lack of need for a peptide or protein substrate.
Inhibitors may bind to a particular kinase in its active state, inactive state, and/or non-ATP binding, or inactive, conformation. 17 Direct measurement of the binding affinity of compounds for the kinase ATP binding site through competition with a labeled binding probe has been reported as an alternative FIG. 1. Schematic representation of 3 biochemical assays used for interleukin-2-inducible T cell kinase (ITK). In the phosphoryl-transfer activity dissociation-enhanced lanthanide fluoroimmuno assay (PT-DELFIA) (A), the kinase transfers the γ-phosphate group from Mg 2+ ATP to the tyrosine hydroxyl group of biotinylated poly(Glu 4 , Tyr 1 ) substrate immobilized on neutravidin-coated microplates. The phosphopeptide product formed is then quantitated in a solid-phase nonhomogeneous format with a europium chelate-labeled antiphosphotyrosine antibody. In the ATPase-LUM (B) assay, the adenosine triphosphate (ATP) depletion resulting from kinase-catalyzed phosphoryl-transfer to a peptide substrate or to water (intrinsic ATPase activity) in a homogeneous format is quantitated with luminescent measurement using luciferase/luciferin reagent (ATP detection reagent), which reacts with the remaining ATP with the formation of light. In the competitive binding fluorescence polarization (CB-FP) assay (C), the fluorescence polarization of the fluorescently labeled small-molecule inhibitor probe is very low and increases significantly on binding to the ATP-binding pocket of the large kinase. Upon competition by an inhibitor, the fluorescence polarization of the labeled probe measurably decreases. GST, glutathione S-transferase. approach for screening kinases. 18, 19 Using a proprietary fluorescent probe, 20 we developed a competitive fluorescence polarization (FP) binding assay for interleukin-2-inducible T cell kinase (ITK; Fig. 1C ).
ITK, a member of the Tec family of nonreceptor protein tyrosine kinases, is activated in T cells and mast cells upon stimulation through the T cell receptor (TCR) and the high-affinity IgE receptor (FcεRI). 21, 22 It regulates airway mast cell degranulation in vivo and prevents the development of both acute and latephase inflammatory allergic reactions. 23 Because ITK displays both phosphoryl-transfer and intrinsic ATPase catalytic activities, it was selected as a candidate enzyme to compare the 3 assay formats. To validate and evaluate the performance of these assays as identifiers of ITK inhibitors, we used them to test a deck of 10,208 compounds selected from the Boehringer Ingelheim (BI) repository based on structural similarity to previously identified kinase inhibitors. The predicted high hit rates for this library were expected to allow for a meaningful comparison of the 3 kinase assays for both their robustness and their ability to identify inhibitor molecules. Initial hits were confirmed by concentration-response testing, from which data were calculated apparent K i or K d values for the inhibitors.
MATERIALS AND METHODS

Materials
Neutravidin-coated 384-well white plates and tris(2carboxyethyl)phosphine (TCEP) were purchased from Pierce (Rockford, IL); black and white 384-well low-volume nonbinding surface (NBS) microplates and 96-well clear roundbottom polypropylene microplates were from Corning (Corning, NY); 384-well polypropylene microplates were from Greiner Bio-One (Longwood, FL); Kinase-Glo luminescent kinase assay reagent was from Promega (Madison, WI); PKLight ATP detection reagent was from Cambrex (Rockland, ME); adenosine 5´-[γ-33 P]triphosphate ([γ33P] ATP), 100 mM ATP solution, and glutathione Sepharose 4B columns were from Amersham/GE HealthCare (Piscataway, NJ); biotinylated poly(Glu 4 , Tyr 1 ) was from CIS-US (Bedford, MA); UniFilter-96 GF/C white Barex microplates, Eu-N1-labeled antiphosphotyrosine PT66 antibody (Eu-PT66), and enhancement solution were from PerkinElmer (Boston, MA); poly(Glu 4 , Tyr 1 ) was from Fluka (Sigma-Aldrich, St. Louis, MO); ultrapure 1M solution of tris(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) buffer, 1M solution of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, and Oregon green 488 carboxylic acid succinimidyl ester (5-isomer) were from Invitrogen (Carlsbad, CA); gentamicin sulfate was from Life Technologies (Gaithersburg, MD); and 5% heat-inactivated fetal bovine serum was from Hyclone (Logan, UT). All other materials were purchased from Sigma-Aldrich (St. Louis, MO) and were of highest purity available.
Expression and purification of ITK
A baculovirus expressing a glutathione S-transferase (GST) fusion protein to the human ITK kinase domain (amino acids 343-620), ITK/KD, was generated using standard methods. 24 Spodoptera frugiperda (Sf21) cells were maintained and infected as described previously 25 using medium supplemented with 5% heat-inactivated fetal bovine serum and 50 µg/mL gentamicin sulfate. All purification procedures were performed at 4 °C. Cytosolic extracts of baculovirus-infected Sf21 cells were prepared as described. 26 Extracts were applied to a glutathione Sepharose 4B column equilibrated in buffer A (20 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM TCEP, 10% v/v glycerol, 0.1 mM ethylenediamine-tetraacetic acid [EDTA], 0.1 mM ethylene glycol-bis-(2-aminoethyl)-N,N,N´, N´-tetraacetic acid [EGTA], and 1 mM phenylmethylsulphonylfluoride [PMSF]). The column was washed with buffer A containing 400 mM NaCl, and GST-ITK/KD protein was eluted in buffer A containing 150 mM NaCl and 10 mM glutathione. Sample purity was verified by SDS-PAGE analysis and electrospray ionization mass spectrometry. The GST tag was removed by thrombin-catalyzed proteolytic cleavage for use in the competitive binding FP assay.
Determination of apparent ATP Km in radiometric assay
A radiometric kinase assay was performed in 50 mM HEPES (pH 7.5), 50 mM KCl, 25 mM MgCl 2 , 5 mM MnCl 2 , 1 mM dithiothreitol (DTT), 50 µg/mL bovine serum albumin (BSA), 100 µM sodium orthovanadate (Na 3 VO 4 ), 0. ATP was serially diluted into wells to cover a broad concentration range across the microplate. The reaction was started by adding 1 nM GST-ITK/KD and terminated by the addition of 10% trichloroacetic acid, 5% sodium pyrophosphate. Phosphorylated products were captured on a UniFilter-96 GF/C white Barex microplate and quantified by scintillation counting in a TopCount. An apparent ATP K m of 12 µM was determined by fitting initial velocity data to the following Henri-Michaelis-
Synthesis of the Oregon green-labeled fluorescent probe
The fluorescent probe 6-(2,7-difluoro-6-hydroxy-3-oxo-3Hxanthen-9-yl)-N-[6-(5-nitro-2-phenylamino-pyrimidin-4ylamino)-hexyl]-isophthalamic acid was synthesized by the method outlined in the synthetic scheme ( Fig. 2) . Twelve grams (61.86 mmol) of 2,4-dichloro-5-nitro-pyrimidine ( Fig. 2, I) [EMKA-Chemie cat. no. 1252] were dissolved in glacial acetic acid (70 mL) and cooled in an ice bath. Potassium thiocyanate (KSCN, 6.31 g, 64.96 mmol) was added, and the reaction was stirred for 2 h. The reaction mixture was diluted with water, and the precipitate formed was recovered by vacuum filtration. The filtrate was washed with ether and dried to product 2-chloro-4thiocyanato-5-nitro-pyrimidine ( Fig. 2 , II) (10.15 g, 75% yield). Compound (Fig. 2, II) (200 mg, 0.92 mmol) was suspended in ethanol (EtOH, 3 mL), and aniline (86 mg, 0.92 mmol) was added dropwise at ambient temperature followed by the addition of triethylamine (TEA, 0.13 mL, 0.92 mmol) via syringe. The resulting mixture was stirred for 2 h at ambient temperature. The precipitate was filtered and dried to (5-nitro-4-thiocyanatopyrimidin-2-yl)-phenyl-amine, which contained 15% of bisadduct (172 mg, 58% yield). This solid product (85 mg, 0.311 mmol) was dissolved in dichloromethane (3 mL). Hexanediamine was added to the reaction, and the mixture was shaken for 16 h at ambient temperature. The reaction mixture was loaded directly onto a flash chromatography column (silica gel) and eluted with a dichloromethane, methanol (MeOH), and ammonium hydroxide gradient. N 4 -(6-Amino-hexyl)-5-nitro-N 2 -phenyl-pyrimidine-2, 4-diamine ( Fig. 2 , III) (80 mg, 78% yield) was isolated as a yellow solid. The diamine ( Fig. 2 , III) (5 mg, 0.01 mmol) and Oregon green 488 carboxylic acid succinimidyl ester (5-isomer) (5 mg, 0.01 mmol) were dissolved in 1 mL of dimethylformamide (DMF) and shaken for 16 h at ambient temperature. The reaction volume was concentrated by rotary evaporation under high vacuum. The residue was loaded onto a preparative thinlayer chromatography (TLC) plate and eluted with a mobile phase of [30% (10% ammonium hydroxide in MeOH) and 70% dichloromethane]. The FP binding fluorescent probe ( Fig. 2, IV) was collected as a bright-orange solid (7 mg, 64% yield).
Phosphoryl-transfer activity DELFIA
The phosphoryl-transfer activity of ITK was performed in white, neutravidin-coated 384-well microplates in 45-µL reaction volumes containing 1 nM GST-ITK/KD, 1.8 µg/mL biotinylated 
Intrinsic ATPase activity luminescence (ATPase-LUM) assay
The intrinsic ATPase activity of GST-ITK/KD was measured using an ATP detection reagent (Kinase-Glo or PKLight) to quantify residual ATP. The assay was performed in 384-well low-volume white NBS microplates in 15-µL kinase reaction volumes containing 20 nM GST-ITK/KD and 0.5 µM ATP in assay buffer consisting of 25 mM HEPES (pH 7.5), 10 mM MgCl 2 , 5 mM MnCl 2 , 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 µM Na 3 VO 4 , 0.5 mM DTT, and 1% DMSO. Negative controls (blanks) were reaction mixtures containing no kinase. The kinase reaction mixture was incubated for 90 min at room temperature. Following incubation, 10 µL of ATP detection reagent diluted in reconstitution buffer was added to the assay plates, incubated at room temperature for 15 min, and relative light unit (RLU) signal was measured on the Analyst in luminescent mode.
Competitive binding FP (CB-FP) assay
The competitive binding FP assay of ITK was conducted in 384-well low-volume black NBS microplates. The assay was performed in 15-µL binding assay volumes containing 250 nM ITK/KD and 25-nM fluorescent probe in assay buffer consisting of 50 mM HEPES, 100 mM NaCl, 5 mM MgCl 2 , 5% glycerol, 0.01% CHAPS, 200 µM TCEP, and 1% DMSO. Negative controls (blanks) were reaction mixtures containing no kinase. After incubating the reaction for 30 min at room temperature, the plates were read on the Analyst in fluorescence polarization mode (excitation 485 nm, emission 530 nm, FL 505 dichroic mirror), and the parallel (I || ) and perpendicular (I ⊥ ) fluorescence intensities as well as the milli-polarization (mP) signals were measured. The affinity of the fluorescent probe for ITK/KD was determined in a titration experiment in which ITK/KD was serially diluted into wells containing the 25-nM fluorescent probe to cover a broad concentration range across the plate. In addition, several wells contained either the probe alone or probe with the highest concentration of ITK/KD to calculate the total intensity of bound probe (Q b )/total intensity of free probe (Q f ) ratio for the probe/kinase domain pair. This Q ratio was required to determine the K p (binding constant for the fluorescent probe) according to the following equation (see appendix):
where r is anisotropy and was calculated from the plate reader I || and I ⊥ fluorescence intensities according to the following relationship:
[R] T is kinase concentration, [P] T is total probe concentration, Q ratio is Q b /Q f , r f is anisotropy for free probe, and r b is anisotropy for bound probe.
Assay development
In validating the assays for high-throughput screening (HTS) of ITK/KD, we optimized conditions for each individual assay, including incubation time, kinase concentration, and substrate/probe concentration. For the phosphoryl-transfer activity DELFIA (PT-DELFIA), we used GST-ITK/KD; biotinylated poly(Glu 4 , Tyr 1 ), which is a generic peptide substrate for tyrosine kinases; and Eu-PT66 antibody to quantitate the phosphopeptide product captured on neutravidin-coated plates. We determined the following optimal concentrations: GST-ITK/KD, 1 nM; biotinylated poly(Glu 4 , Tyr 1 ), 1.8 µg/mL; and Eu-PT66, 1 nM (data not shown). ATP was used at 3 µM, its apparent K m determined in the PT-DELFIA by titrating ATP at 3.6 µg/mL biotinylated poly(Glu 4 , Tyr 1 ) and 1 nM GST-ITK/KD (Fig. 3A) . The kinase reaction showed a linear signal response for up to 60 min at room temperature, and a final assay incubation time of 30 min was chosen. In our initial experiments in the luciferase/luciferin coupled kinase assay, we titrated GST-ITK/KD at 500 nM ATP in the absence or presence of 200 µg/mL peptide substrate poly(Glu 4 , Tyr 1 ). Signal generation is dependent on kinase concentration and also showed
a partial dependence on peptide substrate (Fig. 3B) . To measure the peptide substrate-independent (intrinsic ATPase) activity of GST-ITK/KD, we optimized the ATPase-LUM assay with ATP alone. We determined the optimal concentration of kinase to be 20 nM and ATP to be 500 nM for measuring the intrinsic ATPase activity of GST-ITK/KD in a 90-min reaction at room temperature. For quantitation of ATP remaining after the ATPase reaction in the luminescence assay, we tested Kinase-Glo reagent from Promega as well as PKLight reagent from Cambrex and obtained similar assay results with both detection reagents (data not shown). For the competitive binding fluorescence polarization (CB-FP) assay, the Oregon green-labeled active-site binding fluorescent probe was synthesized using a known ATP competitive inhibitor (core molecule) of ITK. The absorbance, fluorescence excitation, and fluorescence emission spectra were determined (not shown) for the fluorescent probe. The absorbance spectrum was measured to avoid an inner filter effect. The excitation and emission wavelengths of 485 nm and 530 nm, respectively, were selected based on the fluorescence spectra of the probe. The affinity of the binding interaction between the fluorescent probe and ITK/KD was determined from ITK/KD titration experiments performed at the 25-nM probe (Fig. 3C) . The probe K p of 45 nM and Q ratio of 1.06 were determined as described above, and an optimal kinase concentration of 250 nM was selected for the assay.
Compound library screening
We selected 10,208 kinase inhibitor-like compounds from our BI repository to evaluate in the 3 ITK assays described above. The average molecular weight of these compounds is approximately 400 Da. The compounds, dissolved in neat DMSO at 0.3 mg/mL, were diluted to 22.5 µg/mL in assay buffer in 384-well polypropylene microplates. A 2-µL aliquot of this dilution was added to the assay plate (6 µL in the PT-DELFIA plate) for a final concentration of 3 µg/mL (7.5 µM on average) in 1% DMSO, and the assays were performed as described above. Potential interference of the compounds with the luciferase reaction was also tested separately in the absence of kinase in the luminescence assay. Ten-point concentration-response testing of the initial hits (≥ 70% inhibition) was performed as above except that the test compounds were initially dissolved in DMSO at 0.3 mg/mL, then serially diluted 1:3 in assay buffer containing 7.5% DMSO for a final top compound concentration of 3 µg/mL and 1% DMSO in every compound concentration. Plate reader data were analyzed using ActivityBase software (ID Business Solutions, Ltd., Guildford, UK). The RFU signals from PT-DELFIA and mP signals from CB-FP assay were converted to percent of control (POC) values using the following formula:
The RLU signals from the ATPase-LUM assay were converted to POC values using the following formula:
where Signal is the test well signal, BCTRL is the average of background (negative control) well signals on the plate, and PCTRL is the average of positive control well signals on the plate. For concentration-responsive compounds in the catalytic assays, POC as a function of test compound concentration was fitted to a 4-parameter logistic equation of the following form:
where A, B, C, and D are fitted parameters (parameter B is fixed at zero POC), and x and y are the independent and dependent variables, respectively. The IC 50 (50% inhibitory concentration) was determined as the inflection point parameter, C. K i was then calculated from the IC 50 data and ATP K m value, determined in the radiometric assay, according to the following relationship:
For the concentration-responsive compound in the CB-FP assay, K d was calculated by nonlinear least squares regression analysis of the equation (see the appendix):
where [I] T is total inhibitor concentration.
RESULTS AND DISCUSSION
Typical assay metrics for the 3 optimized assays are shown in Table 1 . In the PT-DELFIA, signal increases from blank RFU of 13 ± 6 with no kinase to control RFU of 797 ± 60 with 1 nM kinase. In the CB-FP assay, the signal increases from background mP of 68 ± 7 with probe alone to control mP of 325 ± 3 with 250 nM kinase. In the ATPase-LUM assay, signal decreases The signal values are mean RFU ± SD (n = 24 replicates on one 384-well plate) for the phosphoryl-transfer activity dissociation-enhanced lanthanide fluoroimmuno assay (PT-DELFIA), RLU ± SD (n = 16 replicates on one 384-well plate) for the intrinsic ATPase activity luminescence (ATPase-LUM) assay, and mP ± SD (n = 16 replicates on one 384-well plate) for the competitive binding fluorescence polarization (CB-FP) assay. ITK, interleukin-2-inducible T cell kinase; RFU, relative fluorescent unit; RLU, relative light unit; mP, milli-polarization.
from blank RLU of 372,844 ± 11,032 with no kinase to control RLU of 194,497 ± 6391 with 20 nM kinase. Although the ratio of control/blank signal (blank/control for the ATPase-LUM assay) varies from 60 for PT-DELFIA to 1.9 for the ATPase-LUM assay, typical Z´ statistics 27 of 0.75 in PT-DELFIA, 0.89 in CB-FP, and 0.75 in ATPase-LUM assays reflect their quality. We determined the inhibition constants of a reference inhibitor of ITK in each of the 3 assays (Fig. 4) . The K i values of 66 nM and 72 nM in the PT-DELFIA and the ATPase-LUM assays, respectively, are in good agreement. A slightly higher K d value of 200 nM determined in the CB-FP assay is likely due to the higher concentration of kinase used in this assay as compared to the 2 catalytic activities assay. However, all 3 values are in reasonable agreement with the IC 50 value of 130 nM determined in a radiometric assay (data not shown). We also determined the inhibition constants for staurosporine in the 3 assays. Staurosporine inhibited ITK with a K i of 11 nM in the PT-DELFIA and 14 nM in the ATPase-LUM assay and with a K d value of 71 nM in the CB-FP assay. In addition, both the reference inhibitor and staurosporine completely inhibited the ITK activity in all 3 assays at the highest concentration tested. The ability of both a selective ITK inhibitor as well as a promiscuous kinase inhibitor, staurosporine, to fully inhibit ITK activity to baseline in a peptide substrate-independent luminescence assay further validates intrinsic ATPase activity as a reliable indicator of kinase catalytic activity in this case. This is consistent with the findings that highly purified activated p38α has intrinsic ATPase activity and that inhibitors of ATPase also inhibit the kinase activity with a similar inhibition constant. 13 In separate studies, Ward and O'Brian 14, 28 reported that (1) H7, which inhibits protein kinases but not other ATP-using enzymes by competition with ATP, inhibits the intrinsic ATPase and histone kinase reactions of protein kinase C (PKC) with similar potencies; (2) H7 inhibits the ATPase reaction of PKC with predominantly competitive kinetics; and (3) the ATPase activity of PKC is catalyzed at the active site of the enzyme.
Because the compound library we tested is highly enriched with known kinase inhibitors, we anticipated a high hit rate for ITK in all 3 assay formats. Of the 10,208 compounds tested, 3242 compounds were found to be active in single-concentration testing at ≤ 50 POC (inhibiting more than 50% of the activity) in the PT-DELFIA (32%). The number of initial hits at ≤ 50 POC in the ATPase-LUM and in the CB-FP assays was 3373 (33%) and 2737 (27%), respectively. To reduce the number of compounds for concentration-response testing and to increase the likelihood of acquiring more complete concentrationresponse curves (more than 50% inhibition), we elected to cherry-pick the initial hits inhibiting more than 70% (≤ 30 POC), which reduced the number of initial hits to 2039 in the PT-DELFIA (20%), 2574 in the ATPase-LUM assay (25%), and 1894 in the CB-FP assay (19%). There were a total of 3068 compounds in the combined initial hit set, of which 1444 were common (47% of the total combined initial hit set) for all 3 assays. PT-DELFIA and the CB-FP assay had 1455 common initial hits, PT-DELFIA and the ATPase-LUM assay had 1703 common hits, and the ATPase-LUM assay and CB-FP assay had 1725 common hits. Also, each assay identified unique initial hits-158 in the CB-FP assay, 325 in PT-DELFIA, and 590 in the ATPase-LUM assay. Compounds that inhibit luciferase will appear as negatives in the luminescence assay. By testing the deck of compounds in the luciferase inhibition assay in the absence of ITK at 3 µg/mL, as described in Materials and Methods, we found that only 3 compounds out of 10,208 inhibited more than 30% of the luciferase activity. The POC values for these 3 compounds in the luciferase inhibition assay were 37, 47, and 66. However, none of these compounds was found to be active either in the PT-DELFIA or in the CB-FP assay.
As described in Materials and Methods, without confirmation at the single screening concentration, we quantitated potency of the initial hits (POC ≤ 30 POC) from the primary screens directly in 10-point concentration-response curves run in the 3 ITK assays. For the concentration-responsive compounds, we determined K i values from the PT-DELFIA and the ATPase-LUM assay data and K d values from the CB-FP assay data. The results are summarized in the Venn diagram in Figure 5 . Hit confirmation rate ranged from 84% in PT-DELFIA to 93% in the ATPase-LUM assay, and there is a significant overlap of initial hits returning K i or K d values in all 3 assays. The 3 assays together produced 2472 concentration-responsive hits, with 1409 common (57% shared hits). This indicates a relatively good correlation among the 3 assay formats used for detecting the 3 biochemical activities of ITK, especially considering the observation that different assay technologies measuring the same activity can generate divergent hit sets. [29] [30] [31] [32] [33] For example, a smaller overlap of active compounds was observed when 30,000 compounds were evaluated in 3 different versions of the phosphoryl-transfer activity assay of a tyrosine kinase using scintillation proximity assay (SPA), homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET), and FP technologies. 31 In another study from the same laboratory, about 42,000 compounds were evaluated in a nuclear receptor antagonist assay using 3 assay formats: amplified luminescent proximity homogeneous assay (AlphaScreen), DELFIA, and TR-FRET, which respectively identified 104, 23, and 57 active compounds with only 18 compounds active in all 3 assay formats (17% overlap). 30 Also, the AlphaScreen identified the largest number of functional antagonists. 30 Another group demonstrated greater than 94% overlap of active compounds identified by screening 2133 compounds against the phosphoryl-transfer activity of a serine/threonine kinase using the ATP detection luminescence assay and a microfluidic assay that measures the change in mobility in an electric field of a fluorescently labeled peptide upon phosphorylation. 29 Finally, 95% overlap of active compounds was reported after screening 30,000 compounds against the phosphoryl-transfer catalytic activity of Rho-associated kinase-II (ROCK-II), a serine/threonine kinase, using radiometric filter binding and antibody-based competition FP assays. 33 However, as a percentage of the combined hit sets of the 2 assays (as we calculate our results), the identified actives for ROCK-II from the 2 assays, run under similar assay conditions, is closer to 81% 33 (see the discussion below that our 2 intrinsic ATPase activity assay runs, run under similar conditions but with different ATP detection reagents, also identified confirmed actives with an overlap of 81%). The large number of true active compounds in our test deck may be partly responsible for our high observed cross-assay concordance because the influence of false positives is lower than when intrinsic hit rates are low. 34 However, even in much larger screens with typically low hit rates, well-designed assays using different detection technologies can produce excellent hit set concordance. 35 In this study, 298,689 compounds were screened in pools of 10 for a nonreceptor tyrosine kinase using SPA and TR-FRET assays performed under biochemically equivalent enzymatic reaction conditions. Both assays returned IC 50 values for a total of 297 compounds with 233 in common. Also, the most significant difference reported between the compared techniques is that more false-positive primary hits were obtained in the SPA format. 35 In parallel to the single-point testing, each assay displayed unique concentration-responsive compound hit sets: 18 in the CB-FP assay, 43 in PT-DELFIA, and 510 in the ATPase-LUM assay. Of particular note, the ATPase-LUM assay returned K i values for all but 68 compounds (2.7%) of the combined concentrationresponsive hit set from the 3 assays and missed only 7 compounds out of the combined concentration-responsive hit set from the other 2 assays. Figure 6 shows the correlation of the inhibition constants of the concentration-responsive hits from the 3 assays. PT-DELFIA and the ATPase-LUM assay have 1658 common concentration-responsive hits, and there is a good correlation between the K i values obtained from the 2 distinct catalytic activities assay (Fig. 6A) . PT-DELFIA and the CB-FP assay have 1416 common concentration-responsive hits, and the ATPase-LUM assay and the CB-FP assay have 1645 common concentration-responsive hits. The correlation between the K i values obtained from both the catalytic activities assay and K d values from the CB-FP assay are reasonably good given that these data were generated from different biochemical activities using different assay technologies (Fig. 6B,C) . However, the K d values level out for the most potent compounds, which may be due to an inherent limit imposed by the higher concentration of kinase used in the binding assay. One additional possibility is that each assay may be surveying a potential different conformation of the enzyme.
Because the ATPase-LUM assay produced the most comprehensive hit set and largest number of unique hits, we retested the same deck of 10,208 compounds in this assay using PKLight ATP detection reagent to compare to the first run done using the Kinase-Glo luminescent kinase assay reagent. There was an overlap of 81% with the compounds returning K i values in the assay using ATP detection reagents from 2 different sources. The ATPase-LUM assay using PKLight reagent returned K i values for 2725 compounds (as compared to 2404 with Kinase-Glo), missed 27 compounds out of the combined concentration-responsive hit set from the other 2 assays, and returned 833 unique hits (as compared to 510 with Kinase-Glo). The reasons for the discrepancies are not clear but may be partly due to the limitations of the detection component of the ATPase-LUM assay. Compounds that function as luciferase activators or are luminescent can give rise to false-positive results. Kinase inhibitors that are also luciferase inhibitors or luminescence quenchers (e.g., red compounds) will give falsenegative results. 29 Kinase-Glo reagent from Promega consists of a thermostable luciferase in a proprietary buffer formulation that results in luminescence that is suggested to be much less susceptible to interference from library compounds than other luciferase-based ATP detection reagents (Promega Notes 83, 2003) . However, there is no indication of the presence of such proprietary buffer formulation in the PKLight reagent that is more tolerant of compound interference, and this difference is the subject of current investigations. In addition, by comparing all 4 sets of data generated for ITK, we identified 9 unique compounds that are confirmed inhibitors only in the CB-FP assay. Six of these compounds are intensely colored, and all 9 displayed intrinsic fluorescence at our FP binding assay wavelengths, suggesting that they were false actives by virtue of intrinsic spectroscopic properties. One of the compounds is mercurochrome, a dye related to eosin and fluorescein.
CONCLUSIONS
By screening a deck of 10,208 compounds selected as possible kinase inhibitors against 3 mechanistically distinct biochemical activities of ITK using 3 different assay technologies, we have demonstrated the following: (1) there is a significant overlap of initial hits returning K i or K d values (concentration responsive) in all 3 assays, (2) a good correlation exists between the K i or K d values obtained from the 3 assays, and (3) the intrinsic ATPase activity produced the largest number of unique hits, the fewest unique misses, and returned K i values for all but 2.7% of the combined concentration-responsive hit set of the 3 assays together and missed only 0.5% of the hits agreed upon by the other 2 formats. Measuring intrinsic ATPase activity therefore appears to be a convenient, reliable, and inexpensive way to identify inhibitors of certain protein kinases by HTS. Moreover, we have taken advantage of this activity to screen the same deck of compounds against 21 additional kinases and identified inhibitors with confirmed hit rates ranging from 4.9% to 30.6%. We also screened our BI screening library of ~10 6 compounds against a serine/threonine kinase using intrinsic ATPase activity measurement and identified 2508 inhibitors (as compared to 1748 from the deck of 10,208). However, intrinsic ATPase activity measurement cannot be used as a universal screening format because all kinases do not have this activity. In our experience, 20% of the protein kinases that we have characterized displayed measurable intrinsic ATPase activity. A major advantage of using intrinsic ATPase activity measurement for kinases is reduced assay development time because no peptide or protein substrate is required. To our knowledge, this is the first report demonstrating the use of intrinsic ATPase activity measurement in HTS for the identification of kinase inhibitors, although this activity has been known for some time. [13] [14] [15] [16] [36] [37] [38] One disadvantage of the ATPase-LUM assay is that luciferase inhibitors may be missed, depending on how much overlapping kinase inhibitory activity they display. Such compound interference is relatively rare in our experience, however, and can be eliminated by using new ADP detection technologies such as the Transcreener™ (Bellbrook Labs, Madison, WI) for quantitation of ADP formation after the intrinsic ATPase reaction (Kashem et al., unpublished data), an FP method that detects ADP using a far red ADP-Alexa Fluor ® 633 tracer.
APPENDIX
The competitive, receptor-ligand equilibrium shown in Scheme 1 forms the basis for the most commonly used binding assay in drug discovery to determine the affinity of inhibitors: Scheme 1 P is fluorescently labeled ligand, I is the inhibitor, R is the receptor (kinase in this case), and K p and K d are the equilibrium dissociation constants, respectively.
Many drug discovery assays today involve fluorescence anisotropy, a method that measures the rotational rate of molecules. A small molecular weight probe (P) rotates freely and shows little or no fluorescence polarization. However, upon binding to receptor, its rotational rate assumes that of the much larger molecular weight receptor (R), which rotates much more slowly, and a polarization is observed. Thus, the binding event can be monitored by measuring the probe's rotational rate. A correction, based on the configuration of the instrument, is then applied to the polarization data to give the anisotropy data set.
The expression for measured anisotropy as a function of a free and bound probe 39 is given as follows:
(A1) r f and r b are the anisotropy constants for the free and bound probe, respectively; Ύ f and Ύ b are the fractional fluorescence intensities, respectively. The total fluorescence intensity of any measurement is given by 
.
Expression for the determination of the inhibitor K d
Scheme 1 involves 3 components, and the resulting solution for [R], [RP], or [RI] will be a cubic for which there is no realroot solution. Consequently, assumptions must be made on reactant concentrations to reduce the problem to a quadratic.
An example derivation concerning fluorescence intensity has been previously published, in which the assumption [P] T >> [I] T ≈ [R] T was made. 40 In fluorescence anisotropy, however, it is desirable to keep the receptor in excess over the probe to minimize the signal-to-noise (S/N) ratio. Consequently, the experimental design is based on assuring that [RP] .
